Dapagliflozin, an investigational compound, is a potential first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers ...

the 271 patients assigned to dapagliflozin 5 mg daily achieved a 0.37% decline in HbA1c; the 270 patients assigned to dapagliflozin 10 mg daily achieved a 0.42% decline in HbA1c; the 272 patients ...

The “somewhat unexpected” finding is likely related to the profound impact on health status from the procedure itself.

After this screening, patients were randomly assigned to receive either dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in accordance with the sequestered, fixed-randomization ...

In the ROTATE-3 crossover trial, investigators randomly assigned 46 patients to 3 consecutive 4-week treatments of dapagliflozin 10 mg once daily, eplerenone 50 mg once daily, or a combination of ...

Trial investigators randomized 6,263 patients with an LVEF over 40%, evidence of structural heart disease, and elevated natriuretic peptides to dapagliflozin 10 mg once daily or placebo on top of ...

Within 24 hours of hospital presentation, patients were randomly assigned in a 1:1 ratio to oral dapagliflozin 10 mg once daily or structured usual care until day 5 or hospital discharge.

ORLANDO, Florida — The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly slowed progression of renal dysfunction or death from cardiovascular causes among ...

A total of 328 patients with T2D for less than 6 years were randomly assigned to either calorie restriction alone or calorie restriction with 10 mg dapagliflozin daily for 12 months; the mean age ...

once-daily dose as follows for 24 weeks: Morning dose: placebo (n=75), dapagliflozin 2.5 mg (n=65), dapagliflozin 5 mg (n=64) or dapagliflozin 10 mg (n=70); Evening dose: dapagliflozin 2.5 mg (n ...